Liminatus Pharma (NASDAQ:LIMN – Get Free Report) and Imunon (NASDAQ:IMNN – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
Volatility & Risk
Liminatus Pharma has a beta of 5.35, indicating that its share price is 435% more volatile than the S&P 500. Comparatively, Imunon has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500.
Earnings & Valuation
This table compares Liminatus Pharma and Imunon”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Liminatus Pharma | N/A | N/A | -$10.21 million | ($23.50) | -0.18 |
| Imunon | N/A | N/A | -$14.49 million | ($3.83) | -0.42 |
Imunon is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current recommendations and price targets for Liminatus Pharma and Imunon, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Liminatus Pharma | 1 | 0 | 0 | 0 | 1.00 |
| Imunon | 1 | 0 | 1 | 0 | 2.00 |
Imunon has a consensus target price of $10.00, indicating a potential upside of 525.00%. Given Imunon’s stronger consensus rating and higher probable upside, analysts clearly believe Imunon is more favorable than Liminatus Pharma.
Institutional and Insider Ownership
4.5% of Imunon shares are owned by institutional investors. 19.4% of Liminatus Pharma shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Liminatus Pharma and Imunon’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Liminatus Pharma | N/A | N/A | -256.58% |
| Imunon | N/A | -358.01% | -132.91% |
Summary
Imunon beats Liminatus Pharma on 6 of the 11 factors compared between the two stocks.
About Liminatus Pharma
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
About Imunon
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
